SUPN - Earnings call transcript Q4 2019 | Supernus Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to Supernus Pharmaceuticals Fourth Quarter and Full Year 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Instructions will follow at that time.

As a reminder, this conference call is being recorded.

to Investor conference Pharmaceuticals. Relations, like Vozzo to now Westwicke of representative would turn over the Peter I for Supernus

may begin. You

Peter Vozzo

joining the XXXX these financial Thank thank conference release call. Pharmaceuticals morning, announcing Good the results company quarter us close issued after for press of fourth year you, Supernus the today results. full everyone and Yesterday, for market, Jonathon. you and a

are Patrick. On Chief Supernus' call with the today Chief and available Greg me Jack company's website made Relations Financial Officer, being at Officer, Investor ir.supernus.com. section Today's the Executive is Khattar; the call via of

Following we remarks will questions. call to management, from open the the

forward-looking of future words current believe, other perspective statements forward-looking this course information should, may management on statements existing the trends and similar events make can such company's meaning. regarding the may, by and be identified certain will, anticipate, intend These of reflect During and and as Supernus' call, performance. plan, expect, words future

not statements. the Any of risks may from in in section such Factors Actual forward-looking statements Form Report the Risk XX-K. forward-looking those those guarantees of uncertainties, on materially including and these results performance XXXX noted Annual involve company's differ and future projected are

Eastern related For additional Since to and made call AM topics may is at then, of recorded XXXX have of being the the may announcements on be the Time. benefit the discussed. you X:XX who approximately held those company listening replay, this to February XX,

laws. required releases update securities forward-looking SEC. declines to Supernus recent applicable Please these reference the the as except any company's and current with press filings most statements, obligation by

now turn will the I Jack. over to call

Jack Khattar

for patients as impulsive results. discuss the for results morning, years fourth the of six and the our we join time which treatment year of III release Good to was the in of second Peter. announced XX taking aggression you, full study study old. we PXXX the ADHD everyone, Phase SPN-XXX press XXXX quarter and our yesterday, In thanks to Thank us

was study the weekly double-blind, diagnosed aggression The compared placebo arm. XX% was episodes multi-center, first results and XX% the of effect at clinical the XX% a average It trial in the first much that to parallel-group drug lower primary a frequency randomized frequency design had from the impulsive in missed higher III reduction study. The dose XX% effect Phase much of episodes patients the showing milligram endpoint in similar receiving placebo-controlled, patients placebo the was the study in was where XX to reduction with ADHD. These PXXX Phase differ in III at the reduction. of trial

PXXX the well drug in and was As tolerated. safe the trial

put the results been trial impulsive PXXX SPN-XXX related aggression of the trial have last all announced activities results hold. PXXX Given the year in we the and to from development on

our for by SPN-XXX, remained Regarding We for the with XXXX. SPN-XXX NDA X, date with PDUFA the FDA accepted focus preparing commercial the launch target November potential action review year-end. of on

is an market. ongoing expect SPN-XXX This in in patients by the us by important addition, of end trial expand would with FDA the In the the that Phase SPN-XXX, adult help in use if the III complete adult potentially we the of enrollment approved XXXX. program

preparation SPN-XXX well introduction for in are underway. plans launch the Our of

focus parents and that We have and to initiated that patients. education, several awareness have reach programs broad on disease and

of paradigm discussions treatment the with managed also SPN-XXX the current for plans have We made our importance ADHD. in care regarding progress in

Neurotherapeutics neuro year conferencing, at next the poster as SPN-XXX, ASENT modulating and this important have work Bethesda, the novel and and on In throughout from award scientifically plan its proven week starting action of agent, with norepinephrine We scientific therapies much presentation activity serotonin Maryland. addition, marketplace. a different that it the highlighting publishing we mechanism in XXXX on and the completed a at various is meeting presenting in of existing

disorder, For for III monotherapy pivotal the in of enrollment trial Phase XXXX. the for to ongoing bipolar we bipolar expect treatment through disorders of continue SPN-XXX the treatment

neurology and existing as prescriptions Oxtellar a total the full XXXX. onto reached year increase prescriptions, XXXX, Trokendi for XR for XR IMS, XXX,XXX X.X% over business, reported Moving representing by

grow despite Trokendi the CGRPs XXX,XXX Supernus prescriptions to a decline year in the competition For compared XR managed for by topiramate full increase to the and to intensified representing slight X.X% XXXX, XXXX, market. the

net continued pressure by However, down to sales XXXX in build to XR XXXX. inventory as due care, product Trokendi for from the and were X.X% XXXX managed in compared

representing X% were launch prescription is the over of of for favorably for indication prescriptions in growth This XR XXX,XXX, monotherapy For the year XR XX.X% the compares full due to XXXX. XXXX. in the increase Oxtellar Oxtellar oxcarbazepine and an the XXXX to market

of compared Trokendi XXXX by the net a XR, inventory with but a lesser towards and were of impacted the As sales X.X% sales and net XR in to increase XXXX to degree, comparison in managed care yielding Oxtellar net XXXX. pressure, build

to net last mentioned we our XXXX volume by impact increases sales As growth quarterly deductions. are call any offset in continued earnings be likely price from pressure positive and of on gross to

managed we of competitive pressure of care. a continuation in introduction the expect the CGRP and additional due treatments to XXXX, headwinds migraine For market from

current activity neurology as represent portfolio. in development psychiatry our for XXXX, we strategic that look fit a with and our corporate Finally, assets in continues

I'll Greg full provide to and the call financial our year details will more who on now quarter over performance. turn fourth

Greg Patrick

everyone. and you, Thank morning good Jack

press our and financial results, full to As please year yesterday's XXXX quarter refer I review release. fourth

year comprised Total revenue year million $X and revenue million. XXXX $XXX royalty product for net was to $XXX of million sales for of $XXX XXXX. in was full of million full revenue compared Total XXXX

$X.XX of in of licensing net to compared million and million, product $X royalty million As of revenue $XXX revenue XXXX. sales

be would increase otherwise, to approximately XXXX remain net estimate As in we inventory higher consistent been distributors quarter caused previously quarter disclosed, fourth quarter-to-quarter. this in of XXXX. million had the levels of sales $XX fourth products than year the We the levels pharmacies and wholesalers, that their full product both inventory and company's of have

fourth in This built was XXXX. first effectively inventory reversed of the XXXX in the quarter of quarter

for in the These than primarily first sales product approximately in both quarter As Trokendi been a year fluctuations net otherwise. million have product $XX XR. result, and the would affected net sales full lower XXXX were

Net to full year the million XXXX XXXX year to were for year to $XXX million full product for million XXXX. product $XXX were XXXX full for full for XXXX. Oxtellar $XX for sells XR XXXX. $XX $XXX compared compared for million for full sales XR million year Net full compared Net for year $XXX million year sales Trokendi product were

in quarter of fourth fourth net the XXXX. $XXX XXXX period. fourth sales $XXX and was of prior quarter. million revenue revenue $XXX as included of for to $X product million to and Total year million revenue revenue Total Turning $X million of million the compared product quarter royalty million, of royalty sales compared net in to the $XX

fourth million million million to I product the primarily of for $XX Net build inventory year-over-year fourth to quarter XXXX decrease the were the quarter in the is quarter fourth of described. compared just sales of which due in $XX $XXX XXXX. The XXXX,

were period. million Net primarily full in for year to in net fourth the for of fourth Net the product Oxtellar sales XR sales product product affected Trokendi quarter year million million XR. million $XX were with $XX XXXX. Trokendi quarter compared the results, the for compared XR $XX fluctuations XXXX sales these prior of and $XX XXXX for to As

expenses. development million for to than were year fourth Inc. million the $XX million Turning prior attributable over and upfront and now The quarter respective XXXX lower Research Biscayne to Neurotherapeutics and $XX periods one-time full decrease periods. $XX of the the expenses for XXXX, primarily million $XX approximately of quarter both is year XXXX. the for in fourth $XX million acquisition of expense in

filing. completion four SPN-XXX, for due partially by Phase III to full manufacture was SPN-XXX by the the to In cost the offset of for clinical XXXX addition, our decrease support to SPN-XXX also year trials NDA

unchanged development Oxtellar quarter production XXXX. quarter primarily promotion SG&A of in expenses in the for in expense $XXX million, and million year indication The fourth were fourth XXXX the $XXX to with XR XXXX programs is XXXX SG&A of $XX same of $XX materials decrease from marketing essentially down expenses the the last launch million in quarter the monotherapy SG&A and quarter of the year. for associated the we're million, in of in XXXX. from attributable fourth

In addition, lower. related expenses employee were

for full is in earnings were operating XXXX $XXX due earnings mentioned lower in quarter for primarily XXXX first the as the to I increase draw The Operating XXXX. million down and year inventory expenses in SG&A compared year of the R&D negatively $XXX XXXX. by to Operating earlier. million impacted XXXX full in expenses

$XX were XXXX. year the in compared Operating would in being full operating full the being fourth have $XX XXXX and XXXX earnings quarter otherwise. This higher year of $XX in million $XX to earnings earnings of fourth million quarter lower XXXX than operating been million resulted million

quarterly fourth quarter increase was The been the in million, the have the than by in of operating inventory holdings cause negatively by in XXXX would earnings channel XXXX. fourth comparison to XXXX increase inventory The impacted quarter higher be approximately in $XX aforementioned holdings channel otherwise.

year XXXX. $XXX per per fourth same XXXX year. increase in an $X.XX diluted XX% $XXX compared or $.XXX million or in compared a of full earnings were Net for of diluted quarter $XX were the to as share diluted share, the $XX amount diluted Net per full million per earnings last million or $X.XX XXXX on to share share period million year for $X.X diluted share or

As long-term million $XXX securities, of million December of marketable XX, had of marketable to compared XXXX, XXXX. XX, an and $XXX $XXX cash, in equivalents, company as December the increase securities cash million as

The now range and sales Turning from XXXX. million the company to following: from million. million $XXX for full income providing million, product $XXX to to $XX range $XXX financial year is operating to guidance Net to

in the SPN-XXX, than expenses to in pre-launch of be of expenses expenses, the impact launch the activities reflect SG&A SG&A for salesforce the personnel Higher anticipation consistent XXXX XXXX. of Regarding of quarter-to-quarter primary SPN-XXX. addition are year-over-year other the expected

Thank now back to questions. turn the will the operator for you. call I

Operator

Certainly. [Operator Instructions]

Our first comes line of Ken question Company. from and from Cacciatore Cowen the

please. question, Your

Ken Cacciatore

Hey, good morning, guys.

of Jack, give forward ADHD maybe talk that XXX? the products their think we materially and could be introduction, As a and XXX current you you coverage different why accomplish to branded the than us now about with of sense would can just maybe what pricing the

Thank about on CNS or into about different therapeutic question movement you would are And classes? still development, thinking then business you. thinking venturing and second you be maybe disorders,

Jack Khattar

Sure. Yeah.

as $XXX this its actually the pricing, ADHD, for $XXX the a market to and ranges current whole a the Regarding covers current far prescription basis. are the somewhere non-stimulants, on as $XXX stimulants between brands branded and or and in market concerned XX-day

scientifically as all that that the modulating impacting, as have, remarks, a as interesting side. far receptor to contracting that SPN-XXX fact I some the activity such and to been forth we've and and actually activity the mentioned important of through very the compound. the it's clinical is of care, so where with and product, the to my we becoming mechanism neurotransmitters and highlight And able to on And which actually our really relating prove as data supports managed is far it's the as the very side them, what to really work discussions we've generate in action activity data been able and that novel

I Phase to So, as we're next and that, important currently and programs else where the improving we're presentations Phase similar with we programs, that's more the our product excited And other that very four it week, data continues and the publicly including across where reveal in differentiate to every to in the consistent to that become everybody about ADHD that are in we've through all the from showing hopefully programs marketplace, very actually, has and SPN-XXX is are patients differentiates to III all data itself, later even year. numerous III going first new say posters not. the talked Phase data and on mechanism different this very very with starting you mentioned, non-stimulants predictable about is SPN-XXX times And all II helping symptoms market. so way the clinical and them, the the

mechanism, care with not came it excited as So, last a that all decade of about way novel the a excited that about market data, this acceptance had the we're or they of has even that there seeing plans for understanding novel is we've the more. very that data, start strength the and far this seen out, product also managed is and so truly very -- the discussions

seeing way. they're So, that important they're that it's lot it patients and very really a at, therapy could of benefit a something a as looking much in really differentiated

neurology that that at Regarding psychiatry. does and cover and CNS to with business be intensely looking the development, whole we very domain, involved many continue opportunities we're

We late that them development. find assets continue if to emphasize later stage stage in we assets commercial can are and/or

we are as looking pipeline. conscious to reload well, to that, of fact stuff about really the that earlier the very addition because the need at some we we In are

we to and intention past, And or very raise is that as is to cash to in active, very, we've active to our balance goal something through and to So, do space. active we cash are continue external those in new that be I we flows. our money continue opportunities said, sheet. in very utilize the Obviously, to proceeds our that very hope the we have generate significant on very cash this Certainly, the we been and acquisitions use position bring growth licensing balance and strong year.

Operator

Does that your question? answer you. Thank

Steinberg from David Our question next of in comes Jefferies. line

please. question, Your

David Steinberg

Thanks.

going that your clear you ADHD to the expires be launch -- marketed assets and Trokendi have before asset longer your new Ken's with to pathway come now generics no wanted other Just question is is development, business settlement pretty the to in. on IP follow-up

just -- I wondering, product development So, asset versus asset? to greater an one forward, is is launch a do a there there to on-market with urgency just going stage a

not to the it as high. of I this secondly, the valuation think, i.e. chance the you something I have the past good you a going there's you in transactions, said to too buy said, know sounds then reasons goes you very buyer the one like the of anything, in-license not -- year. or And XX% acquired value seller, you're to Jack, actually

dovetailing does comments, So, in you're that Thank mean attractive seeing you. valuations the more marketplace? your you're

Jack Khattar

Yeah.

for have heard many me now or tell know we I'll higher that. whether -- I not, and everybody people business, I'm say know the of urgency a Regarding and the level urgency mean, I was all mean, you understands reason pharmaceutical this business, a because I time nobody have die -- or we project any level another. one always who there, at -- may

banked will all on So, it or we all really it that way the never make way. make XXX the XXX will fact the

lucky really our program for to been actually in a inception. existence low we've since low, R&D rate So, even our have attrition our such

employees the this data we some -- first the over first for As actually got past ago few on I mentioned to III us our efficacy, the months that safety first data XX ever years. when was work data about Phase XXX, didn't

never the mean, a on -- actually So, I bank yeah, we always straight line. fact that it's

products never guarantee and in an the therefore, that would can You work pipeline you work, your of any with always urgency level.

can a have Given, have reduction XR promotional in. It that and high when we revenue revenue to potential the with the level, situation very Trokendi the as Not we urgency make Yes, sure level the smooth that anyway. products, if generics higher? are come is as the in transition really. possible be to that any as focused on as Is get we them. we far continues

be can done, can and able As -- hope we should far that valuations, we able That's But finding? We we the there. to working effort challenging get promise putting control Unfortunately, be No. to what we really continue we that make think promise the I we be all to we're can it clearly. will we're as hard out pretty and they something happen. can’t.

and involved as very But very the far as at, we've like and predict. something this and different things hope we're certainly get to when at, of looking to a much around date is looking As difficult done. we we're the happens to something been certainty lot

Operator

you. Thank

Our Stifel. from line Samimy comes next from Annabel the question of

question, Your please.

Annabel Samimy

taking for my Hi, guys. question. Thanks

I of to differentiation to SPN-XXX managed want them those what conversation back how the you a efficacy. kind maybe feedback initial care. in of pitching about you been start you talk can terms to made what you've know Just in them are But with back comments go to from about getting conversations.

of to going the hoping was year, the you. towards clarity quarter, And fairly up level down, I consistent the then SG&A I EBITDA fourth sales? then a at through so of It that imagine secondly, up little and of guidance. but steps end or is from is is be on that with new as the stepped year consistent a launch, from Thank that bit significantly it going SG&A for SPN-XXX up where so the the

Jack Khattar

Yeah.

putting Regarding I'll discussions the discussions, well, is care the started to been managed first portion with have them, saying, as the perspective data And we on it we already our Phase which the more with them, with they started we initial the data. in is Explaining current them the getting, market data and were question on tell more have the them the out of we III the feedback therapies clearly the the in discussions you, it satisfied. marketplace. and with share we getting initial

is real discussions to as So, through and to differences, them XXX the the them clear them. data with to different we're walk of explain recently and time took how different? showing And very having we the them points

or And how specifically, them behind in from acknowledge action they've last amphetamine yes, course, XX or and also it come truly or also the drugs. or that years another of do we different saw same everything please reformulation XXX of of And and whatever, methylphenidate case have different data whatever might they the to They the the years mechanism as show is that all me attitude, formulations be. XX don't the of with seen. that were they

Strattera that novel really fact treatment true new this other the patients So, treatment they a it's any a than treatment, like option. fact completely They or new like is the that different non-stimulants. even the presents

versus patients, or or XX at potentially the acknowledge only in conditions, different you different when category molecules or antidepressants have this you schizophrenia product conditions. four XX have CNS where to you options And are where also is they other really products fact a that that look

the to really of XXX and benefit discussions. value these it realize starting the encouraged -- we've can been very So, they're with

question. take I'll the over let on Greg part of the second

Greg Patrick

Thank Annabel. the you, Jack. question, Thanks for

in we major The last regards is continuing did noted that very precursor the of behind to and call, that company's up for the to this and pre-marketing SPN-XXX the launch launch. level stepped marketing As commented activities our is year. activities, preparation note effort a we launch as the of completed think Jack I a much later that

more and So, of R&D out XXXX. couple suggest basis past particularly the reiterate $XX where guidance, a operating income Biscayne we'll And way call, start there range, be And in pretty suggest, in with the a about expenses I'll been million think so I for them let's $XXX SG&A years, $XXX million -- rate about of think that we've to expenses run mentioned would you is that call, in -- ongoing we math and less last our to, over have $XX first, north if XXXX. would consistent as and million for contrast is guess, in to million would reasonable with that acquisition this with the or in use comparison. There's in that as the of an kind pull year. expectation this

You the question -- quarter-to-quarter. asked about very about consistent, that's consistent

So, of year, or I course that over just million the the as relatively looking the bit because the north that, base perhaps like range mentioned. in $XXX them the a of and thinking of being little about activities reflects at pre-marketing of being flat

numbers would a that's XXX. which which quarter be to going salesforce, would the of mentioned, we've the largely adding, addition of exception north that And to of fourth is reps, the company And anticipate one the be activity.

those So, you how back I will that into that, help to math expenses. annualize think

helps. Hope that

Annabel Samimy

you. Thank perfect. That's

Greg Patrick

Welcome.

Operator

you. Thank

Berenberg comes Trucchio of Our from the Patrick next question from line Capital.

please. question, Your

Patrick Trucchio

have picking of to timing good on and talk of that And the the the relative quarters the in time? I for year, lunch should be in XXXX launch quarter Thanks you for of year later or commercial think launch we start fourth SPN-XXX. before being the the that as school Can the XXXX? at of uptick at the morning. three follow-up school XXX on an up would a couple about well more of start the modest in -- therefore underway quarters two being first

level secondly, compound? can of KOLs with on then engagement And is What SPN-XXX? view the your KOLs on also you discuss of this

launch? commercial And finally, build, given when launch would anticipate the late you to expenses start XXXX to

Jack Khattar

with the Okay. the as Yeah. timing far I'll start launch. Patrick, as of

said the X. As November PDUFA we is

we've we we moment plan and So, basically, launch working quickly that the we obviously, pretty as approval will get been to is -- as hard can. the our,

can we and how what get be the is done label product before warehouse. into expecting depending how So, and ready the the X, we can November with label and the quickly

can You few from then, a weeks it's basically. estimate

will to it, we launch even XX it Every soon it if that. or as So, is, going as our we're is quickly possible. intent do count is day whatever to can whenever December launch it

optimize able are year-end But are maximize if out potential regardless it. the launch the school, And it comment, the versus and As when launching we of far that. the love make we of a And at even is school that be around time to to it way said best to we'll to ago couple and ADHD Absolutely. product XXX where back launch we the that obviously, of it back year that. is back as would it do an season? And this launch then to during we've plans ideal point. the are the be to we our, that, years

during all whatever. school if start January no really you in patient demand said the think it that or there's the year, doesn't will a having lot Now, from that, be seeing of December problems there about and surfacing. [ph] kids perspective mean a parents, Because or

getting surface only symptoms beginning one. problems, later surface cards, do or not many struggling these all problems getting surface really year, from those report the of the in year. So don't class, start issues in the letters as of day suspension kids of ADHD Actually, school these are start some the at later the patients on, and issues

during school would Most launched the clearly, year likely, than timeframe. have or summer window it be the uptake slower demand. the been will slower? So, have Will the it yes, around September/October be and we -- will

of little product or uptake, to So, a in January, the it in but yes, the the launch change not before you it we at bit slower, potential long-term, launch in does school. it whether the summertime you all be really expect the December,

results as see far some the it, studies. see KOLs, drug the were firsthand from of we the the it these remarkable, obviously, forth. drug were you, people that we've were just truly the from be III mean, that our course, they they and seeing kids have should whether data, the done. data tell work, firsthand but also as placebo, patients And on III they I but them, KOLs, that I with should first SPN-XXX as Phase saw us study because of everything although, didn't successful they confirmed they tell As even actual And felt experienced, the were always Phase them really I to mean, so shared to not are in blinded, know the the they in

as that in option saw that non-controlled in inattention out the equally very could and non-stimulant, could one, again study effect whole improvement. that shown the that have also work with both an them could and they data as the as a know studies lasted it's early as for and have firsthand there that hyperactivity through they exciting potentially substance to week work And an

to to a milligram XXX to they giving tolerability the we at finally, range dose tolerated, work physicians, behind can is is profile therapeutic them and times sacrificing that this wide the or them very talked that the important safety, this rates discontinuation having the the given with, and And going this well any way window and be giving product low same about and XXX milligram, time all without very -- product. assurance numerous

a Many it. about a what top so many studies. downside It's XXX them even that lose? well really don't of non-controlled to not they It's in of worked they're titration that, like having The easy-to-use. may extremely we trying kids. do have our milligram So, for need even clinical option. for see excited On substance,

So, it is so easy-to-use.

case, And add kids if like pretty these or to worst stimulant know will whether going work is not. for always you to. quickly can You you it a would

received been on and they marketplace. wait have So, the it's really positively KOLs, very to very, us the for can't the product by

XXX of summation the how are get really just on our excitement date hopefully. level excited. that's up every the point as and launch going we So, this and day, where I closer keeps at mean, up we to

Patrick Trucchio

launch And you commercial when then, to just build year? would to start expenses anticipate the this

Greg Patrick

-- previously of in they've mentioned question, since building XXXX. the are Patrick, step a between And are very stepped building terms to expenses embedded as there Annabel's up and up year in been actually, full in the expenses, of launch a XXXX. I XXXX is -- they SG&A significant XXXX

of that So, going this we've launch, year. been spending in and anticipation is really spending to ramp up

the question is, to now. So, answer your

quarter The to the as mentioned, expense. salesforce, launch of the other a to I is in which component and that Annabel's expenses fourth largely response is related question, that's going to be

just added the tweak We approval that prior to those date. so anticipated are are that going reps to

So, essentially I to be an anticipate from that a you would standpoint, expense fourth forecasting think, affair. expense quarter

JackKhattar

understand. the to really all expenses So, fairly only marketing are launch but are the the back expenses the salesforce folks we make that quarters. loaded That's across point really want expense, out spread

not be to be of So, quarters, fairly salesforce loaded half second out itself. back launch It's cost of with the spread going going are the to in year. all like expenses exception across the it's the of the the this

Patrick Trucchio

very helpful. That's much. Thank you

Jack Khattar

Welcome.

Operator

Thank you. Instructions] [Operator

Amsellem Our Piper from line next the from David Sandler. of question comes

question, please. Your

Zachary Sachar

taking David. This Hi, is everyone. for my Zach Thank you on question. for

but or generic were regard you've for me if the to a this, patients sense what to the payer step-through of already I access to Just a a to version of are views ones contracting to potential few quick thinking said through gain what We're your we sorry hoping hoping maybe order in you're a -- initially XXX. in and Intuniv to in get specifically of going Strattera SPN-XXX. on am from of terms

thinking think you've for you're you. but already pricing address secondly, this, that Thank on to in what terms of And I to alluded -- the product?

Jack Khattar

Sure. Yeah.

As it's this ongoing an as the discussion point. mentioned at far as I earlier, payers,

other. have that not a position So, one the taken have or it's we they like final way

-- one. from through And the all aim possible much continue to have will clearly those is coverage the through as as launch. So, day before way our

all I discussions product, they're so to them understand welcome we like and more is it mean, data they're and arm to product this truly the the for that novelty generic referred easy considering have as the more than But doesn't I discussions and a that of very Having the a as make you. and far, share you And the or to continue not said and think starting does Intuniv. as it that, a these mechanism therefore, is with it to different generic open as -- it going products. Strattera with worth that an far

I want work be but help through of also us course, from It SPN-XXX misunderstand these of people my we So, a and to don't products. it, separate lot challenging, have will comments. to will data we

in the to $XXX marketplace, that in comments Regarding be specific price a or what will marketplace, from be. products branded range the in range we the way and is the I asked was about on what the don't $XXX the pricing, make question of of But any pricing before stimulants. all covers products and non-stimulants currently mentioned our to strategy branded somewhere will the

Zachary Sachar

Okay. Thank you.

Jack Khattar

Sure.

Operator

like session This today's any Khattar you. does to further of I'd for the back program Thank the Jack conclude program. remarks. to question-and-answer hand

Jack Khattar

what approval the market decade. getting novel Thank And more approved, for be on the in focused you. than of treatment launch first ADHD to introduced if in be We're a SPN-XXX. the would

are the program from an invest providing in later year. we our and results to R&D plan our on disappointing, SPN-XXX continue update R&D in the pipeline While

growth We corporate opportunities will also continue external through development. to pursue

year. Thank you updating forward us We to for look you throughout this morning. the joining

Operator

your Ladies and you you. program. for Thank does include This the in gentlemen, conference. participation today's thank

day. You Good may disconnect. now

Supernus Pharmaceuticals (SUPN) 26 Feb 202019 Q4 Earnings call transcript